Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention

Young Hoon Jeong, Udaya S. Tantry, Yongwhi Park, Tae Jung Kwon, Jeong Rang Park, Seok Jae Hwang, Kevin P. Bliden, Eun Ha Koh, Choong Hwan Kwak, Jin Yong Hwang, Sunjoo Kim, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 ( CYP2C19*2/*3 , CYP3A5*3) and ATP-binding cassette subfamily B1 (ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients. RESEARCH DESIGN AND METHODS - T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary intervention. Conventional aggregometry and VerifyNow were performed at baseline and at 30 days. The primary end point was absolute change in 20-μM ADP-induced maximal platelet aggregation (ΔMPA20) between baseline and switching values. RESULTS - TRIPLE versus DOUBLE showed greater ΔMPA20 (22.9 ± 11.6 vs.12.7 ± 15.5%; difference, 10.2% [95% CI 4.2-16.3]; P <0.001). Carriage of one (β coefficient, -5.4%; P = 0.162) and two CYP2C19 loss-of-function allele(s) (-8.3%; P = 0.007) were associated with lower ΔMPA20 in DOUBLE - treated patients, but not in TRIPLE-treated patients. CONCLUSIONS - Among T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms.

Original languageEnglish (US)
Pages (from-to)2194-2197
Number of pages4
JournalDiabetes Care
Volume35
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

clopidogrel
Percutaneous Coronary Intervention
Type 2 Diabetes Mellitus
Genetic Polymorphisms
Cytochrome P-450 CYP3A
Platelet Aggregation
Adenosine Diphosphate
Cytochrome P-450 Enzyme System
Research Design
Blood Platelets
Adenosine Triphosphate
Alleles
cilostazol

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. / Jeong, Young Hoon; Tantry, Udaya S.; Park, Yongwhi; Kwon, Tae Jung; Park, Jeong Rang; Hwang, Seok Jae; Bliden, Kevin P.; Koh, Eun Ha; Kwak, Choong Hwan; Hwang, Jin Yong; Kim, Sunjoo; Gurbel, Paul A.

In: Diabetes Care, Vol. 35, No. 11, 11.2012, p. 2194-2197.

Research output: Contribution to journalArticle

Jeong, YH, Tantry, US, Park, Y, Kwon, TJ, Park, JR, Hwang, SJ, Bliden, KP, Koh, EH, Kwak, CH, Hwang, JY, Kim, S & Gurbel, PA 2012, 'Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention', Diabetes Care, vol. 35, no. 11, pp. 2194-2197. https://doi.org/10.2337/dc11-2351
Jeong, Young Hoon ; Tantry, Udaya S. ; Park, Yongwhi ; Kwon, Tae Jung ; Park, Jeong Rang ; Hwang, Seok Jae ; Bliden, Kevin P. ; Koh, Eun Ha ; Kwak, Choong Hwan ; Hwang, Jin Yong ; Kim, Sunjoo ; Gurbel, Paul A. / Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. In: Diabetes Care. 2012 ; Vol. 35, No. 11. pp. 2194-2197.
@article{6d3b1203c3724d7a82e7d281201f1df4,
title = "Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention",
abstract = "OBJECTIVE - To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 ( CYP2C19*2/*3 , CYP3A5*3) and ATP-binding cassette subfamily B1 (ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients. RESEARCH DESIGN AND METHODS - T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary intervention. Conventional aggregometry and VerifyNow were performed at baseline and at 30 days. The primary end point was absolute change in 20-μM ADP-induced maximal platelet aggregation (ΔMPA20) between baseline and switching values. RESULTS - TRIPLE versus DOUBLE showed greater ΔMPA20 (22.9 ± 11.6 vs.12.7 ± 15.5{\%}; difference, 10.2{\%} [95{\%} CI 4.2-16.3]; P <0.001). Carriage of one (β coefficient, -5.4{\%}; P = 0.162) and two CYP2C19 loss-of-function allele(s) (-8.3{\%}; P = 0.007) were associated with lower ΔMPA20 in DOUBLE - treated patients, but not in TRIPLE-treated patients. CONCLUSIONS - Among T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms.",
author = "Jeong, {Young Hoon} and Tantry, {Udaya S.} and Yongwhi Park and Kwon, {Tae Jung} and Park, {Jeong Rang} and Hwang, {Seok Jae} and Bliden, {Kevin P.} and Koh, {Eun Ha} and Kwak, {Choong Hwan} and Hwang, {Jin Yong} and Sunjoo Kim and Gurbel, {Paul A.}",
year = "2012",
month = "11",
doi = "10.2337/dc11-2351",
language = "English (US)",
volume = "35",
pages = "2194--2197",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention

AU - Jeong, Young Hoon

AU - Tantry, Udaya S.

AU - Park, Yongwhi

AU - Kwon, Tae Jung

AU - Park, Jeong Rang

AU - Hwang, Seok Jae

AU - Bliden, Kevin P.

AU - Koh, Eun Ha

AU - Kwak, Choong Hwan

AU - Hwang, Jin Yong

AU - Kim, Sunjoo

AU - Gurbel, Paul A.

PY - 2012/11

Y1 - 2012/11

N2 - OBJECTIVE - To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 ( CYP2C19*2/*3 , CYP3A5*3) and ATP-binding cassette subfamily B1 (ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients. RESEARCH DESIGN AND METHODS - T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary intervention. Conventional aggregometry and VerifyNow were performed at baseline and at 30 days. The primary end point was absolute change in 20-μM ADP-induced maximal platelet aggregation (ΔMPA20) between baseline and switching values. RESULTS - TRIPLE versus DOUBLE showed greater ΔMPA20 (22.9 ± 11.6 vs.12.7 ± 15.5%; difference, 10.2% [95% CI 4.2-16.3]; P <0.001). Carriage of one (β coefficient, -5.4%; P = 0.162) and two CYP2C19 loss-of-function allele(s) (-8.3%; P = 0.007) were associated with lower ΔMPA20 in DOUBLE - treated patients, but not in TRIPLE-treated patients. CONCLUSIONS - Among T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms.

AB - OBJECTIVE - To determine the effect of adding cilostazol (100 mg b.i.d.) to standard-dose clopidogrel (75 mg/d) (TRIPLE) compared with double-dose clopidogrel (150 mg/d) (DOUBLE) and the influence of the cytochrome P450 ( CYP2C19*2/*3 , CYP3A5*3) and ATP-binding cassette subfamily B1 (ABCB1 C3435T) genetic polymorphisms in type 2 diabetes (T2DM) patients. RESEARCH DESIGN AND METHODS - T2DM patients were treated with TRIPLE (n = 41) or DOUBLE (n = 39) after percutaneous coronary intervention. Conventional aggregometry and VerifyNow were performed at baseline and at 30 days. The primary end point was absolute change in 20-μM ADP-induced maximal platelet aggregation (ΔMPA20) between baseline and switching values. RESULTS - TRIPLE versus DOUBLE showed greater ΔMPA20 (22.9 ± 11.6 vs.12.7 ± 15.5%; difference, 10.2% [95% CI 4.2-16.3]; P <0.001). Carriage of one (β coefficient, -5.4%; P = 0.162) and two CYP2C19 loss-of-function allele(s) (-8.3%; P = 0.007) were associated with lower ΔMPA20 in DOUBLE - treated patients, but not in TRIPLE-treated patients. CONCLUSIONS - Among T2DM patients, adding cilostazol achieves greater platelet inhibition compared with clopidogrel (150 mg/d), which is not influenced by genetic polymorphisms.

UR - http://www.scopus.com/inward/record.url?scp=84868089901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868089901&partnerID=8YFLogxK

U2 - 10.2337/dc11-2351

DO - 10.2337/dc11-2351

M3 - Article

C2 - 22837373

AN - SCOPUS:84868089901

VL - 35

SP - 2194

EP - 2197

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -